市場調查報告書

尿激酶的中國市場

Investigation Report on China's Urokinase Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 337515
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
尿激酶的中國市場 Investigation Report on China's Urokinase Market, 2019-2023
出版日期: 2019年08月20日內容資訊: 英文 30 Pages
簡介

本報告提供中國的尿激酶的專利及核準情況,銷售額、銷售量的變化與預測 (過去、今後5年份),價格趨勢,主要的製藥公司和其市場佔有率,競爭環境和其展望,主要製造商的簡介等。

第1章 尿激酶的相關概念

  • 尿激酶的功效
  • 中國的尿激酶市場趨勢
  • 中國的尿激酶的專利取得、政府認證的動向

第2章 中國國內的尿激酶銷售趨勢

  • 尿激酶的銷售額
  • 尿激酶的銷售量
  • 尿激酶的按銷售量:劑型 (過去5年份)

第3章 中國的主要尿激酶、製造商分析

  • 主要廠商的市場佔有率分析
  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

第4章 中國國內的尿激酶的價格

  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

第5章 中國的尿激酶市場未來展望

  • 左右中國的尿激酶市場的要素
    • 推動市場要素與市場機會
    • 威脅與課題
  • 市場規模的預測 (今後5年份)
  • 市場趨勢的預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1908397

Description

Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.

Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.

Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.

Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.

Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI's market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.

It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:

  • Market size of Urokinase in China
  • Competitive landscape of China's Urokinase market
  • Prices of Urokinase in China
  • Favorable and unfavorable factors influencing China's Urokinase market
  • Prospect of China's Urokinase market

Table of Contents

1 Relevant Concepts of Urokinase

  • 1.1 Indications for Urokinase
  • 1.2 Development of Urokinase in China
  • 1.3 Patents and Government Approval on Urokinase in China

2 Sales of Urokinase in China, 2013-2017

  • 2.1 Sales Value of Urokinase
  • 2.2 Sales Volume of Urokinase
  • 2.3 Sales of Urokinase by Dosage Form in China, 2013-2017

3 Analysis on Major Urokinase Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Urokinase Manufacturers
  • 3.2 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 3.3 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 3.4 Livzon Pharmaceutical Factory of Livzon Group
  • 3.5 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 3.6 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

4 Prices of Urokinase in China, 2017-2018

  • 4.1 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 4.2 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 4.3 Livzon Pharmaceutical Factory of Livzon Group
  • 4.4 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 4.5 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

5 Prospect of China's Urokinase Market, 2019-2023

  • 5.1 Factors Influencing China's Urokinase Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Sales of Urokinase in China, 2013-2017
  • Chart Sales Value of Urokinase in Parts of China, 2013-2017
  • Chart Sales Volume of Urokinase in China, 2013-2017
  • Chart Sales Volume of Urokinase in Parts of China, 2013-2017
  • Chart Sales Value of Urokinase Injections in China, 2013-2017
  • Chart Sales Volume of Urokinase Injections in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Livzon Pharmaceutical Factory of Livzon Group, 2013-2017
  • Chart Sales Value of Urokinase by Wuhan Humanwell Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Tianjin Biochemical Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Livzon Pharmaceutical Factory of Livzon Group in Parts of China, 2017
Back to Top